Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05734196 · ClinicalTrials.gov registry record · Phase 1
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
A Phase 1 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum, sponsored by Inozyme Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 7
- Study locations
NCT05734196 is a Phase 1 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum that is actively recruiting participants, run by Inozyme Pharma. The registered enrollment target is 16 participants, below the 79-participant average among 3 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (80% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT05734196, a Phase 1 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum, is actively recruiting participants, sponsored by Inozyme Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
Conditions Studied
Interventions
- DRUG INZ-701
Study Locations (7)
Other
- Hospital Sant Joan de Déu - Barcelona
- Royal Manchester Children's Hospital - Manchester
California
- Rady Children's Hospital - San Diego
Massachusetts
- Boston Children's Hospital - Boston
Ohio
- Nationwide Children's Hospital - Columbus
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Utah
- The University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-06-25 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05734196
The ClinicalTrials.gov registry entry for NCT05734196 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 3 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (80% lower). The listed sponsor is Inozyme Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency appearing as the primary indexed condition, and to 1 intervention - of which INZ-701 is the first listed.
NCT05734196 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05734196 about?
NCT05734196 is a clinical study titled "The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency". The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
What is the current status of trial NCT05734196?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-06-25. Estimated completion is 2026-04-01.
What conditions does trial NCT05734196 study?
This clinical trial studies the following conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Pseudoxanthoma Elasticum, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency.
What interventions are being tested in trial NCT05734196?
The interventions under investigation include: INZ-701 (DRUG).
Who is sponsoring clinical trial NCT05734196?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05734196 being conducted?
This trial has 7 study locations across California, Massachusetts, Ohio, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
COMPLETED · Phase 1
-
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
RECRUITING · Phase 2
-
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
All registered trials for this condition
Pseudoxanthoma Elasticum
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.